FDA May Approve New Opioid That’s 5- to 10-Times Stronger Than Fentanyl [Fortune]
AcelRx Pharmaceuticals, Inc. (ACRX)
Last acelrx pharmaceuticals, inc. earnings: 3/16 07:35 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acelrx.com/investor-relations
Company Research
Source: Fortune
Almost half of all overdose deaths in the United States is caused by Fentanyl , according to research released earlier this summer. So it may seem surprising that the U.S. Food and Drug Administration (FDA) is considering giving approval to AcelRx Pharmaceuticals for Dsuvia, its single-dose 30 microgram tablet of synthetic opioid sufentanil. Sufentanil is five to 10 times stronger than fentanyl and 500 times stronger than morphine, according to Marketwatch . The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee recently voted 10-3 in favor of U.S. approval of Dsuvia. The FDA is not required to but often follows the committee’s recommendations. But even among committee members, there is disagreement about the necessity of releasing another potent opioid to the public. Dr. Raeford Brown, the chair of the committee and a professor of anesthesiology and pediatrics at the University of Kentucky, expressed concern about Dsuvia, which he noted comes in a form
Show less
Read more
Impact Snapshot
Event Time:
ACRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRX alerts
High impacting AcelRx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACRX
News
- AcelRx Announces Rebranding With Name Change to Talphera, Inc. [Yahoo! Finance]Yahoo! Finance
- AcelRx Announces Rebranding With Name Change to Talphera, Inc.PR Newswire
- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
ACRX
Earnings
- 11/8/23 - Beat
ACRX
Sec Filings
- 1/9/24 - Form 8-K
- ACRX's page on the SEC website